Role of Serum Pepsinogen I and II Ratio in Screening of Gastric Carcinoma. 2017

A Begum, and M A Baten, and Z Begum, and M M Ahsan, and S F Rahman, and F Chowdhury, and A H Khan
Dr Ambia Begum, Assistant Professor, Department of Pathology, Community Based Medical College Bangladesh (CBMCB), Mymensingh, Bangladesh.

In spite of the global decline in its incidence and mortality, gastric carcinoma still remains a major cause of death due to cancer. Early detection of gastric carcinoma is expected to reduce mortality rates. The applications of measuring of pepsinogen I and pepsinogen II are useful in screening of gastric carcinoma. This cross sectional comparative study was done to find out the correlation of histopathological pattern of gastric carcinoma with serum pepsinogen I & II ratio in the Department of Pathology, Sylhet MAG Osmani Medical College, Sylhet, Bangladesh from January 2010 to December 2010. For these purpose 40 patients with gastric carcinoma, endoscopically visible and histopathologically proved malignant lesions were enrolled as case group. Forty subjects with normal upper GI endoscopy were taken as control. Five ml of venous blood was taken from both case and control subjects to determine serum pepsinogen I and pepsinogen II level by ELISA method, subsequently pepsinogen I and II ratio was calculated. In this study different cut off values of serum pepsinogen I and II ratio was determined and the sensitivity, specificity, positive predictive value, negative predictive value and accuracy were 70.0%, 97.5% 96.6% 76.5% and 83.8% respectively, at cut off value of 6. Which is the most suitable cut off point of serum pepsinogen I and II ratio for gastric cancer screening.

UI MeSH Term Description Entries
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001459 Bangladesh A country in Southern Asia, bordering the Bay of Bengal, between Burma and India. The capital is Dhaka.
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D055088 Early Detection of Cancer Methods to identify and characterize cancer in the early stages of disease and predict tumor behavior. Cancer Screening,Cancer Screening Tests,Early Diagnosis of Cancer,Cancer Early Detection,Cancer Early Diagnosis,Cancer Screening Test,Screening Test, Cancer,Screening Tests, Cancer,Screening, Cancer,Test, Cancer Screening,Tests, Cancer Screening
D020115 Pepsinogen C This is one of the 2 related pepsinogen systems in humans. It is found in prostate and seminal fluid whereas PEPSINOGEN A is not. Pepsinogen II,Progastricsin
D020116 Pepsinogen A This is one of 2 related pepsinogen systems in humans and is also known as pepsinogen. (The other is PEPSINOGEN C.) This includes isozymogens Pg1-Pg5 (pepsinogens 1-5, group I or products of PGA1-PGA5 genes). This is the main pepsinogen found in urine. Pepsinogen,Pepsinogen 3, Group I,Pepsinogen 5, Group I,Pepsinogen I,Uropepsinogen

Related Publications

A Begum, and M A Baten, and Z Begum, and M M Ahsan, and S F Rahman, and F Chowdhury, and A H Khan
May 2019, Biomolecular concepts,
A Begum, and M A Baten, and Z Begum, and M M Ahsan, and S F Rahman, and F Chowdhury, and A H Khan
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
A Begum, and M A Baten, and Z Begum, and M M Ahsan, and S F Rahman, and F Chowdhury, and A H Khan
January 2003, Nihon rinsho. Japanese journal of clinical medicine,
A Begum, and M A Baten, and Z Begum, and M M Ahsan, and S F Rahman, and F Chowdhury, and A H Khan
April 1981, Annals of internal medicine,
A Begum, and M A Baten, and Z Begum, and M M Ahsan, and S F Rahman, and F Chowdhury, and A H Khan
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
A Begum, and M A Baten, and Z Begum, and M M Ahsan, and S F Rahman, and F Chowdhury, and A H Khan
January 1997, International journal of clinical pharmacology research,
A Begum, and M A Baten, and Z Begum, and M M Ahsan, and S F Rahman, and F Chowdhury, and A H Khan
September 2006, Zhonghua zhong liu za zhi [Chinese journal of oncology],
A Begum, and M A Baten, and Z Begum, and M M Ahsan, and S F Rahman, and F Chowdhury, and A H Khan
July 2009, Acta medica Indonesiana,
A Begum, and M A Baten, and Z Begum, and M M Ahsan, and S F Rahman, and F Chowdhury, and A H Khan
January 2013, Asian Pacific journal of cancer prevention : APJCP,
A Begum, and M A Baten, and Z Begum, and M M Ahsan, and S F Rahman, and F Chowdhury, and A H Khan
January 2007, Internal medicine (Tokyo, Japan),
Copied contents to your clipboard!